ZURICH, Oct 2 (Reuters) - Swiss biotech firm Serono (SEO.VX: Quote, Profile, Research) said on Monday that two Phase II studies using adecatumumab (MT201) as a treatment for metastatic breast cancer and prostate cancer failed to meet their goals but the drug may have some benefits.
